Abstract MP95: Prevalence of General and Abdominal Obesity in Adults with Chronic Kidney Disease: Results from NHANES 2007-2012
Background: Obesity is associated with increased risk for chronic kidney disease (CKD), and may be a modifiable risk factor for its progression. Prevalence of general and abdominal obesity has not been well-described in a nationally-representative sample of adults with CKD.
Methods: We used data from the National Health and Nutrition Examination Survey (NHANES) 2007-2012 to estimate prevalence of obesity [body mass index (BMI) ≥30 kg/m2], severe obesity (BMI ≥35 kg/m2), and elevated waist circumference (World Health Organization guidelines: women ≥ 88 cm; men ≥ 102 cm) in adults ≥ 20 years for individuals with CKD [estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 or albumin/creatinine ratio (ACR) ≥ 30mg/g] overall, and in categories of eGFR and ACR. Correlations between BMI and waist circumference were examined and compared between persons with and without CKD. Continuous relationships between eGFR, log-transformed ACR and obesity were examined using logistic regression, adjusted for age, race, and sex.
Results: Prevalence of obesity, severe obesity, and elevated waist circumference was 43.2%, 20.7%, and 67.4% in adults with CKD compared to 33.5%, 13.7%, and 52.6% in adults without CKD (p<0.001 for all comparisons). Overall, the prevalence of obesity and elevated waist circumference tended to increase with more severe category of eGFR and ACR (Figure). BMI and waist circumference were strongly correlated for both adults with CKD (r=0.89) and without CKD (r=0.9). However, 44.2% of non-obese persons with CKD had elevated waist circumference compared to 30.9% of non-obese persons without CKD (p<0.001). In continuous analyses, obesity was associated with higher ACR, particularly among persons with higher eGFR (p for interaction = 0.1); obesity and eGFR were not independently associated.
Conclusion: Obesity, particularly in a central distribution, is common among individuals with CKD. Clinical trials are needed to determine whether reducing weight can prevent or slow progression of CKD.
Author Disclosures: A.R. Chang: None. L.J. Appel: None. M.E. Grams: None.
- © 2015 by American Heart Association, Inc.